SCHEMBL466550

SCHEMBL466550

C1=C2NCCCCN2CCC1

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.32
GAA P10253 1/20 0.32
POLB P06746 1/20 0.32
CHKA P35790 1/20 0.31
HRH1 P35367 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1782998 0.93 CHRNB2 (0.32)
SCHEMBL929207 0.91 CHKA (0.31) CHKAHRH1
Hydrochloric Acid SCHEMBL11301415 0.89 CHKA (0.30) CHKA
SCHEMBL20550342 0.89
SCHEMBL7877977 0.84
SCHEMBL2819147 0.75
SCHEMBL15364407 0.67 CHRNB2 (0.33)
SCHEMBL6406381 0.65 CHRNB2 (0.33) HRH1
SCHEMBL9904083 0.64 APAF1 (0.34) KDM4EGAAPOLB
SCHEMBL2303095 0.61 ALDH1A1 (0.36) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954353-B2 Process for producing porous materials BASF SE (DE) 2021-03-23 US claimed
EP-2900715-B1 PROCESS FOR THE PREPARATION OF POROUS MATERIALS ON THE BASIS OF POLYURIC MATERIAL BASF SE (DE) 2020-11-25 EP claimed
US-10240020-B2 Process for producing porous materials BASF SE (DE) 2019-03-26 US claimed
EP-3004201-B1 PROCESS FOR PRODUCING POROUS MATERIALS BASF SE (DE) 2017-03-22 EP claimed
US-9321876-B2 Process for producing porous materials based on isocyanate BASF SE (DE) 2016-04-26 US claimed
US-20160090463-A1 PROCESS FOR PRODUCING POROUS MATERIALS BASF SE (DE) 2016-03-31 US claimed
US-20140088215-A1 PROCESS FOR PRODUCING POROUS MATERIALS BASED ON ISOCYANATE BASF SE (DE) 2014-03-27 US claimed
EP-0815074-A1 O-CARBAMOYL-(D)-PHENYLALANILOL COMPOUNDS AND PROCESS FOR PREPARING THE SAME YUKONG LIMITED (KR) 1998-01-07 EP claimed
WO-1996024577-A1 O-CARBAMOYL-(D)-PHENYLALANILOL COMPOUNDS AND PROCESS FOR PREPARING THE SAME YUKONG LIMITED (KR) 1996-08-15 WO claimed
US-20260071043-A1 ARTICLES COMPRISING A COMBINATION OF POLYMER AEROGEL AND MELAMINE-FORMALDEHYDE FOAM AND RELATED SYSTEMS AND METHODS AEROGEL TECHNOLOGIES, LLC (US) 2026-03-12 US disclosed
US-20260071042-A1 SYSTEMS AND METHODS FOR PRODUCING AEROGEL MATERIALS AEROGEL TECHNOLOGIES, LLC (US) 2026-03-12 US disclosed
US-12497732-B2 Polymer-aerogel/fiber and polymer-aerogel/textile composites and related systems and methods AEROGEL TECHNOLOGIES, LLC (US) 2025-12-16 US disclosed
US-12435198-B2 Molding based on a monolithic organic aerogel AEROGEL-IT GMBH (DE) 2025-10-07 US disclosed
US-20250270371-A1 HYDROPHOBIC POLYIMIDE AEROGELS AEROGEL TECHNOLOGIES, LLC (US) 2025-08-28 US disclosed
EP-0873308-A1 O-CARBAMOYL-PHENYLALANINOL COMPOUNDS, THEIR PHARMACEUTICALLY USEFUL SALTS AND PROCESS FOR PREPARING THE SAME SK Corporation (KR) 1998-10-28 EP disclosed
WO-1998015526-A1 O-CARBAMOYL-PHENYLALANINOL COMPOUNDS, THEIR PHARMACEUTICALLY USEFUL SALTS AND PROCESS FOR PREPARING THE SAME SK CORPORATION (KR) 1998-04-16 WO disclosed
EP-0583136-B1 Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders KISSEI PHARMACEUTICAL (JP) 1997-10-08 EP disclosed
WO-1996024577-A1 O-CARBAMOYL-(D)-PHENYLALANILOL COMPOUNDS AND PROCESS FOR PREPARING THE SAME YUKONG LIMITED (KR) 1996-08-15 WO disclosed
US-5294718-A Platelet aggregation inhibitors; antiischemic agents; side effect reduction KISSEI PHARMACEUTICAL CO., LTD. (JP) 1994-03-15 US disclosed
EP-0583136-A2 Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders Kissei Pharmaceutical Co., Ltd. (JP) 1994-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260071042-A1 SYSTEMS AND METHODS FOR PRODUCING AEROGEL MATERIALS TERT, TAF11, TAF1 KDM4E 1196/4885GAA 4829/4885POLB 1363/4885
US-20260071043-A1 ARTICLES COMPRISING A COMBINATION OF POLYMER AEROGEL AND MELAMINE-FORMALDEHYDE FOAM AND RELATED SYSTEMS AND METHODS FLNA, FLNB, FUS KDM4E 1796/4885GAA 4503/4885POLB 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.